Ibrance, Prevnar 13 Q2 Sales Validate Pfizer's R&D Investments
This article was originally published in The Pink Sheet Daily
Novel products help the company beat consensus estimates for the quarter, and the pharma giant pointed to immuno-oncology and PCSK9 as investments that will provide greater returns in the future. Additional acquisitions and a potential split remain on the table, execs say.
You may also be interested in...
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.